A Long-term, Multicenter, Single-arm, Open-label Extension of the SERENADE Study, to Assess the Safety and Efficacy of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Macitentan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms SERENADE OL
- Sponsors Actelion Pharmaceuticals
- 12 Nov 2019 Planned End Date changed from 30 Nov 2023 to 30 Apr 2027.
- 12 Nov 2019 Planned primary completion date changed from 30 Nov 2023 to 4 May 2026.
- 27 Dec 2018 Status changed from not yet recruiting to recruiting.